Nicolas T Labarre, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3217 Mabel St, Shreveport, LA 71103 Phone: 318-631-9121 Fax: 318-631-9126 |
Sathya Jaganmohan, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 8001 Youree Dr Ste 540, Shreveport, LA 71115 Phone: 318-631-9121 Fax: 318-631-9126 |
Meher Sindhoora Mavuram, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3217 Mabel St, Shreveport, LA 71103 Phone: 318-631-9121 Fax: 318-631-9126 |
News Archive
The Obama administration today announced that premiums for Medicare Part B coverage in 2012 will be $99.90 a month for most beneficiaries, a smaller-than-expected increase over the $96.40 paid this year by a majority of elderly and disabled beneficiaries. Part B pays for physician visits, hospital outpatient costs and certain other services. A 3.6 percent Social Security cost-of-living adjustment, the first in three years, will more than make up for the small increase, according to the Department of Health and Human Services.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
University of Hawaii Cancer Center Prevention and Control Program researchers Pallav Pokhrel, PhD and Thaddeus Herzog, PhD have found that smokers who use e-cigarettes as a tool to stop smoking tend to be younger and more motivated to quit smoking as compared to other smokers.
A University of Hawai'i Cancer Center researcher has identified how some cancer cells are made to move during metastasis. The research provides a better understanding of how cancer spreads and may create new opportunities for cancer drug development.
Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.
› Verified 4 days ago